GlassScriptPhysician profile
Susamita Kesh
NPI 1003348004
$9,061.02
in general payments reported to CMS, 2019-2025
28 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $880 · 2023: $4,022 · 2024: $2,104 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,078 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,751 · Education: $213 · Consulting Fee: $33.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,077.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,751.25 |
| Education | $212.94 |
| Consulting Fee | $33.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,260.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,251.76 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $749.92 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $542.18 | 2022-2025 | Xembify |
| Glaxosmithkline, LLC. | $409.34 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $365.68 | 2023-2025 | |
| Blueprint Medicines Corporation | $364.96 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $256.55 | 2023-2025 | Takhzyro, Cuvitru, Hyqvia |
| Abbvie INC. | $212.61 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $178.94 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $156.96 | 2023 | |
| Genentech, INC. | $150.00 | 2022 | |
| Phadia US INC. | $146.28 | 2022-2024 | Immunocap |
| Optinose US, INC. | $142.25 | 2023-2025 | |
| Genentech USA, INC. | $131.25 | 2021-2025 | Xolair |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $114.84 | 2023-2025 | Haegarda, Andembry |
| Organon LLC | $95.89 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $95.28 | 2023 | Dupixent |
| Pfizer INC. | $67.18 | 2024-2025 | |
| Amgen INC. | $55.62 | 2024-2025 | Tezspire |
| Pharming Healthcare, INC. | $53.17 | 2025 | Ruconest |
| Lilly USA, LLC | $53.00 | 2024-2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $44.26 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $43.00 | 2023 | |
| Hikma Pharmaceuticals USA | $36.95 | 2023-2024 | Ryaltris |
| Adma Biomanufacturing LLC | $33.48 | 2023-2025 | |
| Incyte Corporation | $29.45 | 2024 | Opzelura |
| Kaleo, INC. | $19.99 | 2023 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susamita Kesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.